Table 1.
Group | Monkey number | SIV deltaB670 inoculation | AIDSa | ARTb |
---|---|---|---|---|
Control | 44 | No | No | No |
50 | No | No | No | |
69 | No | No | No | |
87 | No | No | No | |
88 | No | No | No | |
SIV/-AIDS | 75 | Yes | No | No |
80 | Yes | No | No | |
85 | Yes | No | No | |
92 | Yes | No | No | |
93 | Yes | No | No | |
SIV/+AIDS | 71 | Yes | Yes | No |
74 | Yes | Yes | No | |
78 | Yes | Yes | No | |
79 | Yes | Yes | No | |
82 | Yes | Yes | No | |
86 | Yes | Yes | No | |
SIV/+AIDS/+6-Cl-ddG | 70 | Yes | Yes | Yes |
72 | Yes | Yes | Yes | |
73 | Yes | Yes | Yes | |
76 | Yes | Yes | Yes | |
77 | Yes | Yes | Yes | |
83 | Yes | Yes | Yes | |
89 | Yes | Yes | Yesc | |
91 | Yes | Yes | Yes |
aClinical manifestation of acquired immunodeficiency syndrome
bAdministration of 2,3-ddl (10 mg/kg s. c. daily) for 3 weeks, following 6-Cl-ddG (75 mg/kg s. c. daily) for 6 weeks
cSole administration of 6-Cl-ddG (75 mg/kg s. c. daily) for 3 weeks